Apogee Therapeutic(APGE.US)

Last Updated 19:00:00 ET
longbridge loading

Canaccord Genuity Sticks to Their Buy Rating for Apogee Therapeutics (APGE)

Tip Ranks·
US
APGE
+1.38%
US
XBI
+0.74%
US
FBT
+0.79%
Tip Ranks·
US
APGE
+1.38%
US
XBI
+0.74%
US
FBT
+0.79%

Apogee Therapeutics shares are trading higher after the company reported better-than-expected Q1 financial results.

benzinga_article·
US
APGE
+1.38%
benzinga_article·
US
APGE
+1.38%

Apogee Therapeutic | 10-Q: FY2026 Q1 Revenue: USD 0

Earnings Watch·
US
APGE
+1.38%
Earnings Watch·
US
APGE
+1.38%

Apogee Therapeutic | 8-K: FY2026 Q1 Revenue: USD 0

Earnings Watch·
US
APGE
+1.38%
Earnings Watch·
US
APGE
+1.38%

Apog appoints resignations of Andrew Gottesdiener and Peter Harwin from board

TradingView·
US
APGE
+1.38%
US
BIB
+0.08%
US
IBBQ
+0.79%
TradingView·
US
APGE
+1.38%
US
BIB
+0.08%
US
IBBQ
+0.79%

How Investors May Respond To Apogee Therapeutics (APGE) CEO Share Sale and US$403 Million Equity Raise

Simplywall·
US
SBIO
+1.98%
US
BIB
+0.08%
US
APGE
+1.38%
Simplywall·
US
SBIO
+1.98%
US
BIB
+0.08%
US
APGE
+1.38%

Apogee Acquisition Corp Announces Closing of $172.5 Million Initial Public Offering | AACP Stock News

StockTitan·
US
AOGO
0.00%
US
APOG
+2.86%
US
APGE
+1.38%
StockTitan·
US
AOGO
0.00%
US
APOG
+2.86%
US
APGE
+1.38%

Apogee Acquisition Corp Announces Pricing of $150 Million Initial Public Offering | AACP Stock News

StockTitan·
US
APGE
+1.38%
US
APOG
+2.86%
StockTitan·
US
APGE
+1.38%
US
APOG
+2.86%
© 2026 Longbridge｜Disclaimer